NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

Search

Coloplast A-S (Class B)

Suletud

419.3 -0.43

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

417.9

Max

423.1

Põhinäitajad

By Trading Economics

Sissetulek

522M

1.4B

Müük

83M

7B

P/E

Sektori keskmine

24.492

60.328

Aktsiakasum

6.32

Dividenditootlus

5.28

Kasumimarginaal

19.835

Töötajad

16,983

EBITDA

309M

2.3B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.28%

2.24%

Järgmine tulemuste avaldamine

12. mai 2026

Järgmine dividendimakse kuupäev

20. mai 2026

Järgmine aktsia dividendi kuupäev (ex-date)

18. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-21B

98B

Eelmine avamishind

419.73

Eelmine sulgemishind

419.3

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23. apr 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23. apr 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23. apr 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23. apr 2026, 22:33 UTC

Tulu

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23. apr 2026, 22:17 UTC

Tulu

PLS Executed Offtake Agreement With Ronbay

23. apr 2026, 22:17 UTC

Tulu

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23. apr 2026, 22:16 UTC

Tulu

PLS Commences Commissioning of Midstream Demonstration Plant

23. apr 2026, 22:15 UTC

Tulu

PLS Group Reaffirms FY26 Guidance for All Metrics

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23. apr 2026, 22:13 UTC

Tulu

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23. apr 2026, 22:12 UTC

Tulu

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:12 UTC

Tulu

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23. apr 2026, 22:11 UTC

Tulu

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23. apr 2026, 22:10 UTC

Tulu

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23. apr 2026, 22:09 UTC

Tulu

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23. apr 2026, 22:08 UTC

Tulu

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23. apr 2026, 22:04 UTC

Tulu

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23. apr 2026, 21:56 UTC

Market Talk
Tulu

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23. apr 2026, 21:27 UTC

Tulu

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23. apr 2026, 21:25 UTC

Tulu

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23. apr 2026, 21:24 UTC

Tulu

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23. apr 2026, 21:24 UTC

Tulu

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23. apr 2026, 21:21 UTC

Tulu

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23. apr 2026, 21:21 UTC

Tulu

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat